The article by King and coworkers in this issue of the Journal (pp. 92–99) reports the results
of BUILD-3, a large, randomized, and placebo-controlled trial that evaluated the efficacy of …

Background The Korea Interstitial Lung Disease Study Group has made a new nationwide
idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed …

Background Atypical idiopathic pulmonary fibrosis (IPF) including multiple cysts or markedly
atelectatic induration in upper lung predominance occasionally can confirm the diagnosis of …

Background Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung
function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs …

OBJECTIVE The outcomes of patients with idiopathic pulmonary fibrosis (IPF) who undergo
hospitalization have not been well characterized. We sought to determine the frequency of …

Background The anti-fibrotic medications nintedanib and pirfenidone were approved in the
United States for use in patients with idiopathic pulmonary fibrosis several years ago. While …

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic pulmonary
disease with rising incidence. In this study the effectiveness of pirfenidone, as measured by …

Rationale: The pathogenic importance of smoking status in idiopathic pulmonary fibrosis
(IPF) is uncertain. In theory, increased oxidative stress in current and former smokers might …

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias and is associated with both a variable clinical course and a poor prognosis …

Extract The antifibrotic medications pirfenidone and nintedanib became the first US Food
and Drug Administration (FDA)-approved medical therapy for the treatment of idiopathic …